siRNA Knockdown of REDD1 Facilitates Aspirin-Mediated Dephosphorylation of mTORC1 Target 4E-BP1 in MDA-MB-468 Human Breast Cancer Cell Line

References

• Betz C, Hall MN. Where is mTOR and what is it doing there? J Cell Biol. 2013;203(4):563–574. doi:10.1083/jcb.20130604124385483
   PubMed Web of Science ®Google Scholar
• Hare SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res. 2017;7(3):383–404.28400999
   PubMed Web of Science ®Google Scholar
• Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors. JAMA Oncol. 2016;2(12):1565–1573. doi:10.1001/jamaoncol.2016.089127388585
   PubMed Web of Science ®Google Scholar
• Dai X, Mei Y, Chen X, Anln CD, Are Jointly KDR. Prognostic of breast cancer survival and can be modulated for triple negative breast cancer control. Front Genet. 2019;10(October):1–11. doi:10.3389/fgene.2019.0079030804975
   PubMed Web of Science ®Google Scholar
• Dai X, Chen X, Hakizimana O, Mei Y. Genetic interactions between ANLN and KDR are prognostic for breast cancer survival. Oncol Rep. 2019;42(6):2255–2266. doi:10.3892/or.2019.733231578580
   PubMed Web of Science ®Google Scholar
• Paplomata E, O’regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6(4):154–166. doi:10.1177/175883401453002325057302
   PubMed Web of Science ®Google Scholar
• Wu KK. Aspirin and Salicylate. Circulation. 2000;102(17):2022–2023. doi:10.1161/01.CIR.102.17.202211044413
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. The mechanism of action of aspirin. Thrombosis res. 2003 110(5). 225. doi:10.1016/S0049-3848(03)00379-7
   Web of Science ®Google Scholar
• Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer. 2014;111(1):61–67. doi:10.1038/bjc.2014.27124874482
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen F, Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag Res. 2018;10:4631–4640. doi:10.2147/CMAR.S17521230410398
   PubMed Web of Science ®Google Scholar
• Chen J, Stark LA. Aspirin Prevention of Colorectal Cancer: focus on NF-κB Signalling and the Nucleolus. Biomedicines. 2017;5:43. doi:10.3390/biomedicines5030043
   PubMed Web of Science ®Google Scholar
• Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges of aspirin and other antiplatelet agents. Blood. 2018;131(16):1777–1789. doi:10.1182/blood-2017-05-74318729519806
   PubMed Web of Science ®Google Scholar
• Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature. 1998;396(6706):77–80. doi:10.1038/239489817203
   PubMed Web of Science ®Google Scholar
• Bos CL, Kodach LL, Van Den Brink GR, et al. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006;25(49):6447–6456. doi:10.1038/sj.onc.120965816878161
   PubMed Web of Science ®Google Scholar
• Din FVN, Valanciute A, Houde VP, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7):7. doi:10.1053/j.gastro.2012.02.050
   Web of Science ®Google Scholar
• Sun D, Liu H, Dai X, et al. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Cancer Lett. 2017;406:105–115. doi:10.1016/j.canlet.2017.06.02928687354
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, et al. Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. N Engl J Med. 2012;367(17):1596–1606. doi:10.1056/NEJMoa120775623094721
   PubMed Web of Science ®Google Scholar
• Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. J Clin Oncol. 2013;31(34):4297–4305. doi:10.1200/JCO.2013.50.032224062397
   PubMed Web of Science ®Google Scholar
• Henry WS, Laszewski T, Tsang T, et al. Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling. Cancer Res. 2018;77(3):790–801. doi:10.1158/0008-5472.CAN-16-2400
   Web of Science ®Google Scholar
• Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18(23):2893–2904. doi:10.1101/gad.125680415545625
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Inoki K, Guan KL. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. 2005;280(11):9769–9772. doi:10.1074/jbc.C40055720015632201
   PubMed Web of Science ®Google Scholar
• Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P. Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals. 2012;5(12):1346–1371. doi:10.3390/ph512134624281340
   PubMedGoogle Scholar
• Savukaitytė A, Vadeikienė R, Laukaitienė D, Ugenskienė R, Juozaitytė E. Salicylic acid plays a major role in aspirin anticancer action in breast cancer cells. Liet Bendr Prakt Gydyt. 2019;23(9):584–588.
   Google Scholar
• Borthwick GM, Sarah Johnson A, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox- independent mechanism. FASEB J. 2006;20(12):2009–2016. doi:10.1096/fj.06-5987com17012253
   PubMed Web of Science ®Google Scholar
• Dachineni R, Ai G, Kumar DR, Sadhu SS, Tummala H, Bhat GJ. Cyclin A2 and CDK2 as novel targets of aspirin and salicylic acid: A potential role in cancer prevention. Mol Cancer Res. 2016;14(3):241–252. doi:10.1158/1541-7786.MCR-15-036026685215
   PubMed Web of Science ®Google Scholar
• Osman A, Hitzler WE, Ameur A, Provost P, Schubert M. Differential expression analysis by RNA-seq reveals perturbations in the platelet mRNA transcriptome triggered by pathogen reduction systems. PLoS One. 2015;10:7. doi:10.1371/journal.pone.0133070
   Web of Science ®Google Scholar
• Li W, Turner A, Aggarwal P, et al. Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis. BMC Genomics. 2015;16(1):1–13. doi:10.1186/s12864-015-2270-125553907
   PubMed Web of Science ®Google Scholar
• Fornecker LM, Muller L, Bertrand F, et al. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. Sci Rep. 2019;9(1):1–9. doi:10.1038/s41598-018-37273-430626917
   PubMed Web of Science ®Google Scholar
• Qin X, Jiang B, Zhang Y. 4E-BP1, a multifactor regulated multifunctional protein. Cell Cycle. 2016;15. doi:10.1080/15384101.2016.115158127649789
   PubMed Web of Science ®Google Scholar
• Mi W, Ye Q, Liu S, She Q-B. AKT Inhibition Overcomes Rapamycin Resistance by Enhancing the Repressive Function of PRAS40 on MTORC1/4E-BP1 Axis. Oncotarget. 2015;6(16):13962–13977. doi:10.18632/oncotarget.3920
   Google Scholar
• Shoshani T, Faerman A, Mett I, et al. Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801, Involved in Apoptosis. Mol Cell Biol. 2002;22(7):2283–2293. doi:10.1128/mcb.22.7.2283-2293.200211884613
   PubMed Web of Science ®Google Scholar
• Deyoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008;22(2):239–251. doi:10.1101/gad.161760818198340
   PubMed Web of Science ®Google Scholar
• Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004;101(3):811–816. doi:10.1073/pnas.030414610114711987
   PubMed Web of Science ®Google Scholar
• Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1. Mol Cell Biol. 2005;25(14):5834–5845. doi:10.1128/mcb.25.14.5834-5845.200515988001
   PubMed Web of Science ®Google Scholar
• Jin HO, Seo SK, Woo SH, et al. Activating transcription factor 4 and CCAAT/enhancer-binding protein-β negatively regulate the mammalian target of rapamycin via Redd1 expression in response to oxidative and endoplasmic reticulum stress. Free Radic Biol Med. 2009;46(8):1158–1167. doi:10.1016/j.freeradbiomed.2009.01.01519439225
   PubMed Web of Science ®Google Scholar
• Whitney ML, Jefferson LS, Kimball SR. ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem Biophys Res Commun. 2009;379(2):451–455. doi:10.1016/j.bbrc.2008.12.07919114033
   PubMed Web of Science ®Google Scholar
• Gordon BS, Steiner JL, Williamson DL, Lang CH, Kimball SR. Emerging role for regulated in development and DNA damage 1 (REDD1) in the regulation of skeletal muscle metabolism. Am J Physiol Endocrinol Metab. 2016;311(1):E157–E174. doi:10.1152/ajpendo.00059.201627189933
   PubMed Web of Science ®Google Scholar
• Horak P, Crawford AR, Vadysirisack DD, et al. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci U S A. 2010;107(10):4675–4680. doi:10.1073/pnas.090770510720176937
   PubMed Web of Science ®Google Scholar
• Koo JS, Jung W. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer. Pathobiology. 2011;77(6):289–300. doi:10.1159/000320936
   Web of Science ®Google Scholar
• Pinto JA, Araujo J, Cardenas NK, et al. A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. Npj Genomic Med. 2016;1(May):2015. doi:10.1038/npjgenmed.2015.15
   Web of Science ®Google Scholar
• Ben SI, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71(13):4366–4372. doi:10.1158/0008-5472.CAN-10-176921540236
   PubMed Web of Science ®Google Scholar
• Liao KF, Chiu TL, Huang SY, et al. Anti-Cancer effects of radix angelica sinensis (Danggui) and N-Butylidenephthalide on Gastric Cancer: implications for REDD1 activation and mTOR inhibition. Cell Physiol Biochem. 2018;48(6):2231–2236. doi:10.1159/00049264130114701
   PubMedGoogle Scholar
• Yun SM, Woo SH, Oh ST, et al. Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells. Mol Cell Endocrinol. 2016;422:64–73. doi:10.1016/j.mce.2015.11.01626607805
   PubMed Web of Science ®Google Scholar
• Avdulov S, Li S, Michalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 2004;5(6):553–563. doi:10.1016/j.ccr.2004.05.02415193258
   PubMed Web of Science ®Google Scholar
• Vadysirisack DD, Baenke F, Ory B, Lei K, Ellisen LW. Feedback control of p53 translation by REDD1 and mTORC1 Limits the p53-Dependent DNA Damage Response. Mol Cell Biol. 2011;31(21):4356–4365. doi:10.1128/mcb.05541-1121896779
   PubMed Web of Science ®Google Scholar
• Molitoris JK, McColl KS, Swerdlow S, et al. Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes. J Biol Chem. 2011;286(34):30181–30189. doi:10.1074/jbc.M111.24542321733849
   PubMed Web of Science ®Google Scholar